

Remarks

Please cancel original Claims 1-22 in their entirety and substitute therefore newly added Claim 23. Original Claims 1-22 were the claims filed in the corresponding PCT application PCT/US00/16297. During the international phase, original Claims 5 and 13 were deleted and the remaining claims were renumbered as Claims 1-20. Claims 1-20, in turn, were the claims filed in the United States national Application No. 10/009,655.

Applicants have proposed amending page 1 of the specification and replacing original Claims 1-22 with newly added Claim 23. Applicants respectfully submit that entry of said amendment will constitute the addition of no new matter to the present application. Said amendment is being proposed simply to claim subject matter disclosed, but not claimed, in the corresponding parent application.

Basis for the subject matter of Claim 23 may be found in the specification on page 26 (Example 1, Compound IV(b), step D).

Entry of this amendment is courteously requested.

Respectfully submitted,



Alexander Wilson
Attorney for Applicants
Registration No. 45,782
Phone: 317-277-0190

Eli Lilly and Company
Patent Division/AW
P.O. Box 6288
Indianapolis, Indiana 46206-6288

08 April 2004.